{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:16:05Z","timestamp":1788196565002,"version":"build-2803163510"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,12]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Cefuroxime, as a second-generation cephalosporin, is widely used in clinical practice. In recent years, research using the Food and Drug Administration Adverse Event Reporting System (FAERS) database has led to new discoveries about the adverse event profile of cefuroxime. However, there is currently a lack of systematic research on the safety of cefuroxime based on the Japan Adverse Drug Event Report (JADER) database. This study analyzed the clinical characteristics and adverse event signals associated with cefuroxime using the JADER database and further compared the findings with those from the FAERS database. A descriptive analysis was conducted on the clinical characteristics of adverse event reports associated with cefuroxime, including report year, report season, onset time, reporter type, sex, age, weight, dose, frequency, and indication. Four disproportionality algorithms were employed to identify adverse event signals. Subsequently, the clinical characteristics and disproportionality signals of cefuroxime in the JADER database were contrasted with those in the FAERS database. A total of 60 adverse event reports and 132 adverse events related to cefuroxime were identified from the JADER database. \u201cOculomucocutaneous syndrome\u201d emerged as a newly identified disproportionality signal in the JADER database, which was neither reported in the FAERS database nor previously documented in cefuroxime\u2019s labeling. \u201cAnaphylactic shock,\u201d \u201cdrug-induced liver injury,\u201d \u201cjaundice,\u201d and \u201cStevens-Johnson syndrome\u201d were identified as disproportionality signals in both the JADER and FAERS databases. \u201cAnaphylactic shock\u201d had a stronger signal in the FAERS database, and \u201cdrug-induced liver injury\u201d and \u201cjaundice\u201d exhibited stronger signals in the JADER database. This study provides a descriptive analysis and signal detection using the JADER database, contributing to previous research based solely on the FAERS database and offering an additional perspective on the clinical safety profile of cefuroxime. This finding suggests a potential need for enhanced monitoring for \u201cskin and subcutaneous tissue disorders,\u201d \u201cimmune system disorders,\u201d and \u201chepatobiliary disorders.\u201d It should be noted that the results from the JADER and FAERS databases may be influenced by reporting biases. Therefore, further studies are warranted to corroborate the findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049232","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:02:05Z","timestamp":1781600525000},"page":"e49232","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive analysis of cefuroxime-associated adverse events: Insights from JADER database (2004\u20132024) and comparison with FAERS database"],"prefix":"10.1097","volume":"105","author":[{"given":"Fangqiong","family":"Li","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China"},{"name":"Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyu","family":"Luo","sequence":"additional","affiliation":[{"name":"Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8454-749X","authenticated-orcid":false,"given":"Cheng","family":"Jiang","sequence":"additional","affiliation":[{"name":"Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"},{"name":"Zhejiang Key Laboratory of Disease-Syndrome Integrated for Cancer Prevention and Treatment, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China"},{"name":"Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Pharmacodynamic Material Basis Research of Chinese Medicine, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqin","family":"Xia","sequence":"additional","affiliation":[{"name":"Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"},{"name":"Department of Infection Prevention and Control, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260831","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/0250-474X.180242","article-title":"Pharmaceutical evaluation of cefuroxime axetil tablets available in drug market of Pakistan.","volume":"78","author":"Israr","year":"2016","journal-title":"Indian J Pharm Sci"},{"key":"R2-20260831","doi-asserted-by":"crossref","first-page":"112829","DOI":"10.1016\/j.ejmech.2020.112829","article-title":"Beta-lactam antibiotics: an overview from a medicinal chemistry perspective.","volume":"208","author":"Lima","year":"2020","journal-title":"Eur J Med Chem"},{"key":"R3-20260831","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12876-019-1056-3","article-title":"Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin.","volume":"19","author":"Song","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"R4-20260831","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40780-017-0088-5","article-title":"Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databases.","volume":"3","author":"Hatahira","year":"2017","journal-title":"J Pharm Health Care Sci"},{"key":"R5-20260831","doi-asserted-by":"crossref","first-page":"1251961","DOI":"10.3389\/fphar.2024.1251961","article-title":"A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.","volume":"15","author":"Pan","year":"2024","journal-title":"Front Pharmacol"},{"key":"R6-20260831","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s40360-025-00960-w","article-title":"Exploration of adverse event profiles for cefotaxime: a disproportionality analysis using the FDA adverse event reporting system.","volume":"26","author":"Jiang","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"R7-20260831","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/antibiotics12020240","article-title":"Electrolyte disorders associated with piperacillin\/tazobactam: a pharmacovigilance study using the FAERS database.","volume":"12","author":"Seo","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"R8-20260831","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12959-022-00369-z","article-title":"Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database.","volume":"20","author":"Guo","year":"2022","journal-title":"Thromb J"},{"key":"R9-20260831","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s15010-024-02248-3","article-title":"Safety evaluation of ceftazidime\/avibactam based on FAERS database.","volume":"52","author":"Zhang","year":"2024","journal-title":"Infection"},{"key":"R10-20260831","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40801-021-00268-1","article-title":"Delirium associations with antibiotics: a pharmacovigilance study of the FDA adverse event reporting system (FAERS).","volume":"9","author":"Teng","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"R11-20260831","doi-asserted-by":"crossref","first-page":"107524","DOI":"10.1016\/j.ijantimicag.2025.107524","article-title":"Association of antibiotics with Stevens-Johnson syndrome and toxic epidermal necrolysis: a real-world pharmacovigilance study.","volume":"66","author":"Yan","year":"2025","journal-title":"Int J Antimicrob Agents"},{"key":"R12-20260831","doi-asserted-by":"crossref","first-page":"20420986241258049","DOI":"10.1177\/20420986241258049","article-title":"A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime.","volume":"15","author":"Jiang","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"R13-20260831","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40360-025-00856-9","article-title":"Drug-related macular edema: a real-world FDA adverse event reporting system database study.","volume":"26","author":"Li","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"R14-20260831","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pds.4944","article-title":"Quality evaluation of the Japanese Adverse Drug Event Report database (JADER).","volume":"29","author":"Tsuchiya","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R15-20260831","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.2147\/DDDT.S81998","article-title":"Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.","volume":"9","author":"Nomura","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"R16-20260831","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1248\/bpb.b19-00156","article-title":"Evaluation of the expression time of ganciclovir-induced adverse events using JADER and FAERS.","volume":"42","author":"Ando","year":"2019","journal-title":"Biol Pharm Bull"},{"key":"R17-20260831","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.3233\/JAD-210524","article-title":"Safety of memantine in combination with potentially interactive drugs in the real world: a pharmacovigilance study using the Japanese Adverse Drug Event Report (JADER) database.","volume":"82","author":"Sato","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"R18-20260831","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12888-025-06493-0","article-title":"A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases.","volume":"25","author":"Lou","year":"2025","journal-title":"BMC Psychiatry"},{"key":"R19-20260831","doi-asserted-by":"crossref","first-page":"20420986231154075","DOI":"10.1177\/20420986231154075","article-title":"Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database.","volume":"14","author":"Altebainawi","year":"2023","journal-title":"Ther Adv Drug Saf"},{"key":"R20-20260831","doi-asserted-by":"crossref","first-page":"377","DOI":"10.18433\/jpps33020","article-title":"Post-marketing safety of vemurafenib: a real-world pharmacovigilance study of the FDA adverse event reporting system.","volume":"25","author":"Liu","year":"2022","journal-title":"J Pharm Pharm Sci"},{"key":"R21-20260831","doi-asserted-by":"crossref","first-page":"20601","DOI":"10.1038\/s41598-022-23726-4","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib.","volume":"12","author":"Guo","year":"2022","journal-title":"Sci Rep"},{"key":"R22-20260831","doi-asserted-by":"crossref","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for osimertinib.","volume":"12","author":"Yin","year":"2022","journal-title":"Sci Rep"},{"key":"R23-20260831","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40257-024-00889-6","article-title":"Update on Stevens-Johnson syndrome and toxic epidermal necrolysis: diagnosis and management.","volume":"25","author":"Shah","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"R24-20260831","first-page":"52","article-title":"Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"90","author":"Liotti","year":"2019","journal-title":"Acta Biomed"},{"key":"R25-20260831","first-page":"102","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in Hong Kong.","volume":"30","author":"Cheung","year":"2024","journal-title":"Hong Kong Med J"},{"key":"R26-20260831","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/bjd\/ljae321","article-title":"Recent progress in Stevens-Johnson syndrome\/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment.","volume":"192","author":"Hama","year":"2024","journal-title":"Br J Dermatol"},{"key":"R27-20260831","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1177\/10783903241252810","article-title":"Stevens-Johnson Syndrome, toxic epidermal necrolysis: macules, papules, and bullae.","volume":"30","author":"Vossos","year":"2024","journal-title":"J Am Psychiatr Nurses Assoc"},{"key":"R28-20260831","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/14740338.2022.2106367","article-title":"Managing the ADR of Stevens-Johnson syndrome\/toxic epidermal necrolysis.","volume":"21","author":"Lian","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"R29-20260831","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ajem.2024.04.001","article-title":"High risk and low prevalence diseases: Stevens Johnson syndrome and toxic epidermal necrolysis.","volume":"81","author":"van Nispen","year":"2024","journal-title":"Am J Emerg Med"},{"key":"R30-20260831","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-Johnson Syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States.","volume":"138","author":"Micheletti","year":"2018","journal-title":"J Invest Dermatol"},{"key":"R31-20260831","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/bjo.67.6.393","article-title":"Slow-release artificial tear inserts in the treatment of dry eyes resulting from the oculomucocutaneous syndrome.","volume":"67","author":"Wright","year":"1983","journal-title":"Br J Ophthalmol"},{"key":"R32-20260831","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000060736","article-title":"Clinical and immunological characteristics of oculomucocutaneous disorders.","volume":"30","author":"Pleyer","year":"1999","journal-title":"Dev Ophthalmol"},{"key":"R33-20260831","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.jaip.2018.01.020","article-title":"Cross-reactivity and tolerability of cephalosporins in patients with IgE-Mediated hypersensitivity to penicillins.","volume":"6","author":"Romano","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R34-20260831","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1345\/aph.1K050","article-title":"Anaphylactic shock associated with cefuroxime axetil: structure-activity relationships.","volume":"41","author":"Hasdenteufel","year":"2007","journal-title":"Ann Pharmacother"},{"key":"R35-20260831","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3390\/nu13020519","article-title":"Health benefits of plant-based nutrition: focus on beans in cardiometabolic diseases.","volume":"13","author":"Mullins","year":"2021","journal-title":"Nutrients"},{"key":"R36-20260831","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/00365521.2017.1291719","article-title":"Drug-induced liver injury due to antibiotics.","volume":"52","author":"Bjornsson","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"R37-20260831","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.3390\/cimb44100317","article-title":"Influence of antibiotics on functionality and viability of liver cells in vitro.","volume":"44","author":"Doss","year":"2022","journal-title":"Curr Issues Mol Biol"},{"key":"R38-20260831","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/jac\/dkr159","article-title":"Hepatic safety of antibiotics used in primary care.","volume":"66","author":"Andrade","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R39-20260831","doi-asserted-by":"crossref","first-page":"101355","DOI":"10.1016\/j.jcmgh.2024.05.003","article-title":"Interplay between drug-induced liver injury and gut microbiota: a comprehensive overview.","volume":"18","author":"Li","year":"2024","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"R40-20260831","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3390\/cimb46020078","article-title":"Gut-liver axis as a therapeutic target for drug-induced liver injury.","volume":"46","author":"Tao","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"R41-20260831","first-page":"121","article-title":"Effect of Rhei Radix et Rhizoma and Eupolyphaga Steleophaga on liver protection mechanism based on pharmacokinetics and metabonomics.","volume":"16","author":"Feng","year":"2024","journal-title":"Chin Herb Med"},{"key":"R42-20260831","first-page":"375","article-title":"Bioactive components, pharmacological properties and underlying mechanism of Ganoderma lucidum spore oil: a review.","volume":"16","author":"Liu","year":"2024","journal-title":"Chin Herb Med"},{"key":"R43-20260831","first-page":"667","article-title":"Inula britannica ameliorates alcohol-induced liver injury by modulating SIRT1-AMPK\/Nrf2\/NF-\u03baB signaling pathway.","volume":"16","author":"Meng","year":"2024","journal-title":"Chin Herb Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:01:53Z","timestamp":1788195713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":43,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049232","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"2025-12-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}